At a recent CGD staff presentation of our work into COVID-19 vaccines, our colleagues raised a large number of interesting questions, so, we asked our colleagues to send in their questions on the COVID-19 vaccine portfolio.
CGD Policy Blogs
Today we launch an interactive tool that analyses the COVID-19 vaccine portfolio, and generates estimates about the timelines for the vaccines in the portfolio.
Monday Morning Vaccine Breakthrough: Terrific News for the West, but in LMICs Terms and Conditions Apply
This morning, America (and much of the world) woke up to a snippet of terrific news: Pfizer and BioNTech announced their SARS-CoV2 vaccine candidate showed 90 percent efficacy. But for policymakers in low- and middle-income countries, today’s news offers limited cause for celebration—and the Pfizer/BioNTech results may even lengthen the timeline for eventual LMIC access.
To attain and sustain universal health coverage, we must harness the power of healthcare innovation. But how can we do so when in many settings, these innovations do not align with local priorities?
Making the $12 Billion Go Further: Four Things the World Bank Can Do in Support of COVID-19 Vaccination Efforts
To maximise the impact of this badly needed investment to combat COVID and, most importantly, to avoid any perverse and potentially catastrophic implications of World Bank financing undermining current global efforts led by Gavi and CEPI, we propose that the World Bank commit to the four principles below.
Our new paper aims to answer this question using mathematical modelling and expert interviews to: better understand the COVID-19 vaccine portfolio, and generate probabilistic estimates on timelines for approval and the manufacturing scale up.
In this blog, we review the good and the bad about where the world now stands in efforts to bringing a vaccine to market, from the perspective of payers, national governments, and country coalitions, as well as development partners.
We are developing a system of interconnected models which represent global manufacturing capability from the start of clinical trials to secondary vaccine manufacture; that is, time from first human trials to finished product ready to be shipped.
Around the world COVID-19 and the policy responses to it are causing unprecedented disruptions of life and wellbeing. As scientists and governments around the world race to develop a vaccine at scale, we take a look at what a portfolio approach entails and why it is so important.
The global race to develop a COVID-19 vaccine is far from conventional. An effective vaccine would offer one of the few credible exit paths from the world’s worst public health and economic crisis in recent history. Is a pull for R&D essential or optional?